1-deoxynojirimycin has been researched along with Inflammation in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 7 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Donida, B; Dos Reis, BG; Faverzani, JL; Hammerschmidt, TG; Kessler, RG; Machado, AZ; Moura, AP; Moura, DJ; Reinhardt, LS; Sebastião, FM; Vargas, CR | 1 |
| Duan, W; Jiang, L; Li, XY; Liu, J; Lu, L; Shi, H; Wang, X; Yang, J; Yu, S; Zhai, M; Zhang, L; Zhu, H | 1 |
| Ampawong, S; Aramwit, P; Fongsodsri, K; Kanjanapruthipong, T; Reamtong, O; Rujimongkon, K; Thaipitakwong, T | 1 |
| D'Alonzo, D; Dechecchi, MC; Esposito, A; Fenza, M; Gregorio, E; Guaragna, A; Lippi, G; Tamanini, A | 1 |
| Chung, YC; Hyun, C-; Hyun, SB | 1 |
| Doguchi, S; Hariya, N; Kondo, S; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Dwek, RA; Hill, ML; Martinez, FO; Miller, JL; Perera, N; Sayce, AC; Tyrrell, BE; Zitzmann, N | 1 |
| Blank, PS; Cluzeau, CV; Cologna, SM; Dail, MK; Lieberman, AP; Porter, FD; Siebel, S; Toth, CL; Wassif, CA; Yanjanin, NM | 1 |
| Goda, T; Harazaki, T; Imai, C; Inoue, S; Mochizuki, K | 1 |
| Hughes, DA; Mehta, A; Thomas, AS | 1 |
| Aureli, M; Bassi, R; Bezzerri, V; Cabrini, G; Cantù, C; Cavazzini, A; Cheng, SH; Dechecchi, MC; Gambari, R; Giri, MG; Lampronti, I; Loberto, N; Lovato, V; Marchetti, N; Munari, S; Sonnino, S; Tebon, M | 1 |
| Aerts, JM; Arbeeny, C; Aten, J; Bijl, N; Dubbelhuis, PF; Ghauharali-van der Vlugt, K; Groen, AK; Ottenhoff, R; Overkleeft, HS; Seeman, I; van Eijk, M; van Roomen, CP | 1 |
| Butters, TD; d'Azzo, A; Dwek, RA; Elliot-Smith, E; Jeyakumar, M; Perry, VH; Platt, FM; Smith, DA; Thomas, R; van der Spoel, AC | 1 |
| Butters, T; Dwek, R; Frendeus, B; Platt, F; Svanborg, C; Svensson, M | 1 |
2 review(s) available for 1-deoxynojirimycin and Inflammation
| Article | Year |
|---|---|
Synthesis and Therapeutic Applications of Iminosugars in Cystic Fibrosis.
Topics: 1-Deoxynojirimycin; Anti-Inflammatory Agents; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Glycoside Hydrolases; Glycosyltransferases; Heterocyclic Compounds, 1-Ring; Humans; Imino Pyranoses; Inflammation; Molecular Structure; Mutation; Sequence Deletion; Tartrates | 2020 |
Gaucher disease: haematological presentations and complications.
Topics: 1-Deoxynojirimycin; Anemia; Combined Modality Therapy; Disease Management; Enzyme Replacement Therapy; Gaucher Disease; Genetic Predisposition to Disease; Glucosylceramidase; Glycosphingolipids; Hemorrhagic Disorders; Humans; Inflammation; Lewy Body Disease; Lysosomes; Macrophage Activation; Multiple Myeloma; Parkinson Disease; Splenectomy; Splenomegaly; Thrombocytopenia; Unfolded Protein Response | 2014 |
1 trial(s) available for 1-deoxynojirimycin and Inflammation
| Article | Year |
|---|---|
S100 Genes are Highly Expressed in Peripheral Leukocytes of Type 2 Diabetes Mellitus Patients Treated with Dietary Therapy.
Topics: 1-Deoxynojirimycin; Adult; Aged; Cytokines; Diabetes Mellitus, Type 2; Fasting; Female; Gene Expression Regulation; Hospitals, University; Humans; Hypoglycemic Agents; Inflammation; Leukocytes; Male; Middle Aged; Prospective Studies; RNA, Messenger; S100 Proteins | 2021 |
11 other study(ies) available for 1-deoxynojirimycin and Inflammation
| Article | Year |
|---|---|
Cytokine profile and cholesterol levels in patients with Niemann-Pick type C disease presenting neurological symptoms: in vivo effect of miglustat and in vitro effect of N-acetylcysteine and coenzyme Q10.
Topics: 1-Deoxynojirimycin; Acetylcysteine; Antioxidants; Cholesterol; Cytokines; Enzyme Inhibitors; Humans; Inflammation; Niemann-Pick Disease, Type C; Ubiquinone | 2022 |
1-Deoxynojirimycin attenuates septic cardiomyopathy by regulating oxidative stress, apoptosis, and inflammation via the JAK2/STAT6 signaling pathway.
Topics: 1-Deoxynojirimycin; Animals; Antiviral Agents; Apoptosis; Cardiomyopathies; Cytokines; Heart Diseases; Hypoglycemic Agents; Inflammation; Janus Kinase 2; Janus Kinases; Lipopolysaccharides; Mice; Oxidative Stress; Reactive Oxygen Species; Sepsis; Signal Transduction | 2022 |
Mulberry-Derived 1-Deoxynojirimycin Prevents Type 2 Diabetes Mellitus Progression via Modulation of Retinol-Binding Protein 4 and Haptoglobin.
Topics: 1-Deoxynojirimycin; Diabetes Mellitus, Type 2; Haptoglobins; Humans; Inflammation; Insulin Resistance; Morus; Plant Extracts; Plant Leaves; Powders; Prediabetic State | 2022 |
Nojirimycin suppresses inflammation via regulation of NF-κ B signaling pathways.
Topics: 1-Deoxynojirimycin; Animals; Anti-Inflammatory Agents; Cell Survival; Cyclooxygenase 2; Cytokines; Inflammation; Inflammation Mediators; Lipopolysaccharides; MAP Kinase Signaling System; Mice; Molecular Structure; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; RAW 264.7 Cells; Signal Transduction | 2020 |
Pathogen-induced inflammation is attenuated by the iminosugar MON-DNJ via modulation of the unfolded protein response.
Topics: 1-Deoxynojirimycin; Anti-Inflammatory Agents; Antigens, Fungal; Cells, Cultured; Cytokines; Dengue Virus; Endoplasmic Reticulum; Host-Pathogen Interactions; Humans; Inflammation; Lipopolysaccharides; Macrophages; Primary Cell Culture; Sepsis; Toll-Like Receptor 4; Unfolded Protein Response | 2021 |
Human and mouse neuroinflammation markers in Niemann-Pick disease, type C1.
Topics: 1-Deoxynojirimycin; Adolescent; Alleles; Animals; Biomarkers; Brain; Cerebellum; Cerebral Cortex; Chemokine CCL3; Chemokine CXCL5; Child; Child, Preschool; Complement C3; Disease Models, Animal; Female; Gene Expression Regulation; Humans; Infant; Infant, Newborn; Inflammation; Interleukins; Male; Mice; Mice, Inbred BALB C; Mice, Transgenic; Niemann-Pick Disease, Type C; Young Adult | 2014 |
Inhibition of postprandial hyperglycemia by either an insulin-dependent or -independent drug reduces the expression of genes related to inflammation in peripheral leukocytes of OLETF rats.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression; Hyperglycemia; Hypoglycemic Agents; Inflammation; Insulin; Interleukin-18; Interleukin-1beta; Leukocytes, Mononuclear; Male; Pyrimidines; Rats; Rats, Inbred OLETF; Receptors, Interleukin-1; S100 Proteins; Sucrose; TNF Receptor-Associated Factor 2 | 2013 |
GBA2-encoded β-glucosidase activity is involved in the inflammatory response to Pseudomonas aeruginosa.
Topics: 1-Deoxynojirimycin; beta-Glucosidase; Bronchi; Cystic Fibrosis; Epithelial Cells; Glucosylceramidase; Glycoside Hydrolase Inhibitors; Humans; Inflammation; Pseudomonas aeruginosa; Pseudomonas Infections | 2014 |
Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation.
Topics: 1-Deoxynojirimycin; Adamantane; Adipogenesis; Adiponectin; Adipose Tissue; Animals; Chemokine CCL2; Glucose; Glycosphingolipids; Homeostasis; Inflammation; Insulin Resistance; Macrophages; Mice; Mice, Inbred C57BL; Mice, Obese; Signal Transduction | 2009 |
Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
Topics: 1-Deoxynojirimycin; Animals; Antigens, CD; Apoptosis; Biomarkers; Blood-Brain Barrier; Cytokines; Enzyme Inhibitors; Gangliosidoses; Gangliosidoses, GM2; Gangliosidosis, GM1; Genes, MHC Class II; Immunohistochemistry; Inflammation; Mice; Sandhoff Disease; Tay-Sachs Disease | 2003 |
Carbohydrate receptor depletion as an antimicrobial strategy for prevention of urinary tract infection.
Topics: 1-Deoxynojirimycin; Bacterial Adhesion; Escherichia coli; Escherichia coli Infections; Fimbriae, Bacterial; Glycolipids; Glycosphingolipids; Humans; Inflammation; Urinary Tract Infections | 2001 |